


HEART FAILURE GUIDELINES FOR U M



14th & 15th
October
2019


7th edition

Better understand the heart failure guidelines process and its implications

Location

Le Saint Paul Hotel
29 boulevard Franck Pilatte
Nice - France

Heart Failure Guidelines Forum Program



Monday 14th October 2019

12h00 – 12h45: Welcome discussions & lunch

13h00 – 13h30: **Session 1** – Heart failure guidelines process – Rules of engagement - **Chairs: S. Anker and P. Seferovic**

- The EU HF guidelines approach - **P. Ponikowski**
- The US HF guidelines approach - **I. Piña**
- The importance of real-world evidence (RWE) in HF guidelines - **P. Seferovic**
- 2019 Clinical Practice Update – HFA Consensus Paper - **A. Coats**
- Discussion

13h30 – 14h10: **Session 2** – Targeting diabetes and pre-diabetes - **Chairs: S. Anker and A. Coats**

- Prevention of HF using SGLT2-inhibitors - **P. Seferovic**
- Treatment of HF using SGLT2-inhibitors (the DAPA-HF example) - **S. Solomon**
- Ongoing SGLT2-inhibitor trials in HF? What about class effects? - **J. Butler**
- Discussion: SGLT2-inhibitors for everyone?! and as first line therapy?! How much data is needed for (entirely) non-diabetics to get a strong recommendation?

14h10 – 15h00: **Session 3** – Diagnosis of HFpEF and its treatment considered in the context of the definition of HFrEF - **Chairs: A. Coats and J. Butler**

- What about Beta-blockers, Candesartan and Spironolactone for HFmrEF (LVEF 40-49% HF) - **K. Swedberg**
- PARAGON-HF results & implication: If we accept Sac/Val for HFrEF, is there much left for it in HFpEF? - **S. Solomon**
- Re-defining HFpEF?! - **M. Packer**
- Discussion: How often can we change the name of the disease(s) before we lose credibility? What is the meaning of subgroups for GLs? And what about sex-specific GLs for HF?! Should a HFrEF cut-point be data driven? Should the cut-point be where below it drugs work? Or where above it drugs don't work? Should any such discussion err on the conservative side and require validation?

15h00 – 15h30: BREAK

15h30 – 16h10: **Session 4** - Devices and telemedicine - **Chairs: S. Anker and J. Butler**

- Intra-atrial shunts – the status 2019 - **W. Abraham**
- Hemodynamic Phenotyping in Heart Failure Trials - **G. Hasenfuß**

- Discussion: place in algorithm, if successful? what is the name of the HF entity the trials recruit?
- Telemedicine a la TIM-HF-II, CardioMems and ReDS - **J. Cleland**
- Discussion: place in algorithm, if successful? what is the name of the HF entity the trials recruit? Are these therapies country specific?

16h10 – 16h30: **Session 5** - Targeting central sleep apnoea - **Chairs: S. Anker and W. Abraham**

- Update on phrenic nerve stimulation (the remedē® system) - **A. Coats**
- Discussion

16h30 – 16h50: BREAK

16h50 – 18h00: **Session 6** – The world of targeting Functional MR - **Chairs: S. Anker and A. Coats**

- COAPT perspective - **W. Abraham**
- Mitra-FR – 2yrs results update - **P. Guerin**
- Proportionate vs disproportionate MR - **M. Packer**
- RESHAPE-HF2 update - **P. Ponikowski**
- PASCAL – data and positioning - **S. von Bardeleben**
- Carillon – data and positioning - **H. Sievert**
- What do future devices have to prove? What about non-inferiority designs? - **N. Mewton**
- Discussion

18h00 – 18h50: **Session 7** – Treatment algorithms for HFrEF - **Chairs: S. Anker and J. Butler**

- Considerations in the development of the 2016 treatment algorithm - **A. Voors**
- Time for a specific treatment algorithm for symptom improvement in HF? - **J. Butler**
- General Discussion 1: Should Sacubitril/Valsartan be considered first line therapy — if so, in whom? Should SGLT2-inhibitors be considered first line therapy — if so, in whom?
- How to add new medications to an algorithm in the future? The challenges of adherence to recommended doses and the therapeutic algorithm in clinical guidelines – the OM example - **A. Coats**
- General Discussion 2

18h50 – 19h20: **Session 8** – Ad hoc Q & A session (part 1)

FROM 20h00: NETWORKING DINNER

Tuesday 15th October 2019

08h20 – 09h40: **Session 9** – Acute HF & Symptomatic HF - **Chairs: A. Coats and J. Butler**

- Guidelines & risk assessment - **L. Stevenson**
- Copeptin for prognostic assessment and therapy guidance in acute HF. - **M. Möckel**
- Discussion
- Guidelines & patient-reported outcomes (PROs) - **L. Stevenson**
- 6MWT-distance for acute & chronic HF: how much evidence is enough for GLs without having M&M data? - **A. Voors**
- iv-iron for HF – state of affairs - **S. Anker**
- Discussion: What if a drug has positive trials on M&M (1) and PROs (1) – does that fulfill the 2-trial rule for IA? How important is the duration of trials for making recommendations?
- Monitoring weight change and wetness of acute HF patients - **W. Abraham**
- Discussion: Only in subgroups of patients? How much change is a clinically meaningful change?

09h40 – 10h30: **Session 10** – What about guidelines implementation recommendations and supportive care to enable GDMT - **Chairs: S. Anker and A. Coats**

- Recommending a HF team approach – all just lip service? - **K. Dickstein**
- Review of evidence (or lack thereof) for current GL recommendations regarding the treatment of HK: diuretics & RAASi down-titration? - **M. Böhm**
- Discussion
- Enablement of RAASi using potassium binders – the available evidence - **J. Butler**
- Discussion: Shall we change the treatment paradigm of hyperkalaemia to enable or optimize RAASi therapy? And what about prevention of hyperkalemia mediated toxicity as an endpoint (as for PPI and anti-coagulation)? Can a series of mid-size enablement studies make it into the GLs?

10h30 – 10h50: BREAK

10h50 – 11h30: **Session 11** – Heart failure in special populations - **Chairs: S. Anker and W. Abraham**

- How do account for frailty, stroke, cardio-oncology in the guidelines - **G. Rosano**
- Guidelines and the cost of therapy – the Tafamidis case for amyloid CM - **A. Coats**
- Regulators Perspective - **FDA / EMA representatives**
- Discussion

11h30 – 12h30: **Session 12** – TMA interactive discussion on guidelines - **Discussion chair: C. Schoen (TMA)**

International panel: **J. Zhang (China), C. Lam (Singapore), T. Imamura (Japan), V. Rastogi (India)**

Questions to the panel and meeting faculty:

- What about international guidelines?
- What about GLs & comments on what to do when resources are limited?
- Are we always dependent on large RCTs? How can small RCTs or RWE help?

12h30 – 12h55: **Session 13** – Ad hoc Q & A session (part 2)

12h55 – 13h00: Final comments and close

LUNCH DISCUSSIONS

Why a Heart Failure Guidelines Forum?

The objective is to better understand the existing Heart Failure guidelines development process and its implications in clinical practice. It is not to develop new guidelines, but to gather a multidisciplinary panel of leading international experts to discuss the latest evidence, ongoing research and controversial issues that have implications for the development of clinical practice guidelines.

Educational objectives

At the end of the meeting, all participants will have a better understanding of the unmet needs and knowledge gaps that need to be addressed by future research and development efforts, and of the most appropriate ways of progressing to conciliate and take advantage of clinical, societal, evidence-based medicine and regulatory requirements.

This event is registered with MedTech Europe and declared (provisionally) compliant: <https://www.ethicalmedtech.eu/>

Meet our panelists

Chairs



Prof. William Abraham

MD, FACP, FACC, FAHA,
FESC, FRCPE

Professor of Medicine,
Physiology, and Cell Biology
College of Medicine,
Distinguished Professor,
Division of Cardiovascular
Medicine, the Ohio State
University, USA



Prof. Stefan Anker

MD, PhD, FESC

Professor of cardiology
and Cachexia Research,
Department of Cardiology
Charité Campus Virchow-
Klinikum Berlin, Germany



Prof. Javed Butler

MD, MPH, MBA

Professor and Chairman
of the Department of
Medicine at the University
of Mississippi in Jackson,
Mississippi, USA, Patrick
H. Lehan Chair in
cardiovascular Research,
Professor of physiology



Prof. Andrew Coats

DM, DSc, MBA, AO

President-elect, Heart
Failure Association of the
ESC, Academic Vice-
President Monash-Warwick
Alliance, Monash University,
Melbourne, Australia,
University of Warwick,
Coventry, UK

Experts

- Michael Böhm, Germany
- John Cleland, UK
- Kenneth Dickstein, Norway
- Gerasimos Filippatos, Greece
- Patrice Guerin, France
- Gerd Hasenfuß, Germany
- Karen Hicks, USA (FDA)
- Teruhiko Imamura, Japan
- Carolyn Lam, Singapore (R)*
- Marco Metra, Italy (R*)
- Nathan Mewton, France
- Martin Möckel, Germany
- Milton Packer, USA
- Ileana Piña, USA
- Piotr Ponikowski, Poland
- Krishna Prasad, UK
- Vishal Rastogi, India
- Giuseppe Rosano, UK
- Petar Seferovic, Serbia
- Horst Sievert, Germany
- Scott Solomon, USA (R*)
- Lynne Stevenson, USA
- Karl Swedberg, Sweden
- Stephan Von Bardeleben, Germany
- Adriaan Voors, The Netherlands
- Jian Zhang, China

*Remote

Contact us

Organization

Charles Schoen - Operations Director

Tel.: +33 (0) 6 08 18 77 08

Email: charles.schoen@tmacademy.org

Registration

Yann Colardelle

Tel.: + 33 (0) 6 71 91 99 77

E-mail: yanncol@mededgs.com

Information :

www.tmacademy.org

An opportunity to meet
a panel of international experts
in **Heart Failure**

HEART FAILURE
GUIDELINES
FOR U M

